Swedish company, Aerocrine has gained approval to market Niox Mino in South Korea and Taiwan.
Niox Mino, a hand-held device is used for the measurement of airway inflammation and monitoring of patients with asthma.
Niox Mino airway inflammation monitor provides accurate, reproducible and immediate measurement of fractional exhaled nitric oxide (FENO).
The move hepls the company to receive reimbursement from public as well as private health insurances on the South Korean and Taiwanese markets.
Asthma is caused by a chronic inflammation in the airway, and is estimated that the number of asthmatics to globally increase from 300 million to 450 million by 2025.